Shandong Sito Bio-technology Co Ltd - Asset Resilience Ratio
Shandong Sito Bio-technology Co Ltd (300583) has an Asset Resilience Ratio of 0.35% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2019)
This chart shows how Shandong Sito Bio-technology Co Ltd's Asset Resilience Ratio has changed over time. Check how strategically is Shandong Sito Bio-technology Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Shandong Sito Bio-technology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300583 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥10.00 Million | 0.35% |
| Total Liquid Assets | CN¥10.00 Million | 0.35% |
Asset Resilience Insights
- Limited Liquidity: Shandong Sito Bio-technology Co Ltd maintains only 0.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shandong Sito Bio-technology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shandong Sito Bio-technology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Shandong Sito Bio-technology Co Ltd (2017–2019)
The table below shows the annual Asset Resilience Ratio data for Shandong Sito Bio-technology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 6.81% | CN¥203.36 Million ≈ $29.76 Million |
CN¥2.99 Billion ≈ $437.13 Million |
-14.84pp |
| 2018-12-31 | 21.64% | CN¥561.57 Million ≈ $82.18 Million |
CN¥2.59 Billion ≈ $379.65 Million |
-5.96pp |
| 2017-12-31 | 27.61% | CN¥558.88 Million ≈ $81.78 Million |
CN¥2.02 Billion ≈ $296.26 Million |
-- |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more